Abstract: A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.

Abstract: A compound of formula (Ic) wherein X2 represents a —CO—NRk— group, wherein Rk represents a hydrogen atom or a methyl group, a —NH—CO—NH— group, a —OCH2— group, a —CH(OH)— group, a —NH—CO— group, a —O— group, a —O—(CH2)s—O—, a —CO— group, a —SO2— group, a divalent 5-membered heteroaromatic ring comprising 1, 2, 3 or 4 heteroatoms, a —NH—SO2— or a —SO2—NH— group; Y2 represents a hydrogen atom, a halogen atom, a hydroxyl group, a (C1-C4)alkoxy group, a a group, a group, a morpholinyl group, optionally substituted by a (C1-C4)alkyl group, a piperazinyl group, a piperidinyl group, or a —CR1R2R3 group, or any of its pharmaceutically acceptable salt.

Abstract: A computer-implemented method for determining and quantifying modes of activation of biological pathways in individual cells, including: receiving sequencing data obtained by a single-cell RNA sequencing method, and a plurality of gene lists, determining a gene-cell expression matrix based on the sequencing data and the plurality of gene lists, carrying out a principal component analysis (PCA) on said gene-cell expression matrix, so as to determine a plurality of modes of activation of at least one among the biological pathways, selecting a subset of so-called effective modes of activation among the plurality of modes of activation, determining a matrix referred to as activity matrix, the activity matrix including scores quantifying a level of activity of each effective mode of activation among the subset of effective modes of activation within each individual cell among the set of individual cells.

Abstract: In vitro or ex vivo methods for screening a quinoline derivative, or anyone of its pharmaceutically acceptable salt, presumed effective in treating and/or preventing an inflammatory disease, the method including: providing an eukaryotic cell, bringing into contact said cell with a quinoline derivative, measuring an expression of miR-124 in the cell, and selecting the candidate presumed effective in treating and/or preventing an inflammatory disease when the level of expression of miR-124 measured is increased relatively to a reference value.

Abstract: The present disclosure relates to a method for selecting a tumor neoantigenic peptide wherein said method comprises: a step of identifying, among mRNA sequences from cancer cells of a subject, a fusion transcript sequence comprising a transposable element (TE) sequence and an exonic sequence, and including an open reading frame (ORF), and a step of selecting a tumor neoantigenic peptide of at least 8 amino acids, encoded by a part of said ORF of the fusion transcript sequence, wherein said ORF overlaps the junction between the TE and the exonic sequence, is pure TE and/or is non-canonical, and wherein said tumor neoantigenic peptide binds to at least one Major Histocompatibility Complex (MHC) molecule of said subject. The present disclosure also relates to tumor neoantigenic peptide obtained according to the present method, vaccine or immunogenic composition, antibodies and immune cells derived thereof and their use in therapy of cancer.

Abstract: The present application relates to a computer-implemented method for identifying at least one class of at least one biological image, notably to predict the genomic signature from biological image(s), in particular to predict Homologous Recombination DNA-repair deficiency (HRD) from biological images of tissues. The present application further proposes a computer-implemented method for visualizing clusters of sub-images or tiles of at least one biological image, in particular to predict the phenotypic feature or combination of phenotypic features (or phenotypic patterns) associated with the genomic signature.

Abstract: The manufacture and use of compounds of formula (Ia) or a pharmaceutically acceptable salt thereof for preventing, inhibiting or treating cancer, AIDS and/or premature aging. The compounds of formula (Ia) being: where: R independently represents a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —CN group, a hydroxyl group, a —COOR1 group, a (C1-C3)fluoroalkyl group, a —NO2 group, a —NR1R2 group, or a (C1-C3)alkoxy group; R? is a hydrogen atom, a halogen atom, a (C1-C3)alkyl group, a —NO2 group, a (C1-C3)alkoxy group, or a —NR1R2 group; and R1 and R2 are a hydrogen atom or a (C1-C3)alkyl group.

Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Abstract: A compound of formula (I) or any of its pharmaceutically acceptable salt for use in the treatment and/or prevention of a RNA virus infection, and a RNA virus infection from group IV or V of the Baltimore classification wherein R3 represents a chlorine atom or a hydrogen atom, R represents a (C1-C4)alkyl group, a (C3-C6)cycloalkyl group, a halogen atom, a (C1-C5)alkoxy group, a —SO2—NRaRb group, a —SO3H group, a —OH group, a —O—SO2—ORc group or a —O—P(?O)—(ORc)(ORd) group, R1 represents (i) a CF3 group, (ii) a (C1-C10)alkyl group, (iii) a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group or (iv) a phenyl group or a naphthyl group, and R2 represents a hydrogen atom, a (C1-C10)alkyl group, a (C3-C6)cycloalkyl or a (C3-C6)heterocycloalkyl group and further relates to new compounds, to pharmaceutical compositions containing them and to synthesis process for manufacturing them.

Abstract: Provided herein is a method for detecting a tumour that can be applied to cell-free samples, to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (CpG islands, CpG shores, and/or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and/or distribution of tumour signals may be used for tumour detection or classification.

Abstract: The invention relates to methods and pharmaceutical compositions for the treatment and diagnosis of cancer. The invention also relates to methods and pharmaceutical compositions for the treatment of inflammatory diseases and autoimmune diseases. The inventors investigate the role and specific contribution of extracellular vesicles (EVs) in cancer environment. The inventors demonstrate that CSF1-associated EVs induce macrophage signature associated with T cell infiltration and extended patient survival. The inventors demonstrate that via specific extracellular vesicles, these tumors promote pro-inflammatory macrophages correlated with better clinical outcome and a better prognosis in TNBC patients. In the present invention, the inventors provide in vitro evidences towards a direct role of CSF1-associated EVs as tools, alone or with other immuno-therapies, to promote anti-tumor immune responses.

Abstract: Provided herein is a method for detecting a tumour that can be applied to cell-free samples, to cell-free detect circulating tumour DNA. The method utilizes detection of adjacent methylation signals within a single sequencing read as the basic positive tumour signal, thereby decreasing false positives. The method comprises extracting DNA from a cell-free sample obtained from a subject, bisulphite converting the DNA, amplifying regions methylated in cancer (CpG islands, CpG shores, and/or CpG shelves), generating sequencing reads, and detecting tumour signals. To increase sensitivity, biased primers designed based on bisulphite converted methylated sequences can be used. Target methylated regions can be selected from a pre-validated set according to the specific aim of the test. Absolute number, proportion, and/or distribution of tumour signals may be used for tumour detection or classification.

Abstract: The present disclosure relates to a method for detecting a mutation in a microsatellite sequence locus of a target fragment from a DNA sample, comprising a step of subjecting said DNA sample to a digital polymerase chain reaction (PCR) in the presence of a PCR solution comprising: a pair of primers suitable for amplifying said target fragment of the DNA sample including said microsatellite sequence; a first MS oligonucleotide (MS) hydrolysis probe, labeled with a first fluorophore, wherein said first MS oligonucleotide probe is complementary to a wild-type sequence including the microsatellite sequence; a second oligonucleotide reference (REF) hydrolysis probe, labeled with a second fluorophore, wherein said second oligonucleotide REF probe is complementary to a wild-type sequence of said target DNA fragment which does not include said microsatellite sequence.

Abstract: The invention relates to tumor-associated FOLR2+ macrophages and gene signature thereof as a biomarker of favorable outcome and anti-tumor immunity useful for the prognosis and monitoring of cancer patients. The invention relates also to FOLR2+ macrophages as a therapeutic target for enhancing T cell immunity in the prevention and treatment of cancer and infectious diseases.

Abstract: A method for preparing a compound of formula (I), a powder, and a pharmaceutical composition are disclosed. The method includes: (i) reacting a compound of formula (II) with a compound of formula (III), to form the hydrochloride salt of the compound of formula (I), and (ii) recovering the compound of formula (I) in the form of a free base through addition of a base. In step (i), the molar ratio of the compound of formula (II) to the compound of formula (III) is in a range of from 1.00:0.80 to 1.00:1.20, and no metal catalyst is present. A powder including the composition of formula (I) may be obtained by the method. The powder may have a particle size distribution with specific D50, D90 and/or D10 values. A pharmaceutical composition may include the powder and at least one pharmaceutically acceptable excipient.

Abstract: A compound of Formula (I): or anyone of its metabolites or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein each R is independently hydrogen, halogen, —CN, hydroxyl, (C1-C3)fluoroalkyl, (C1-C3)fluoroalkoxy, (C3-C6)cycloalkyl, —NO2, —NR1R2, (C1-C4)alkoxy, phenoxy, —NR1—SO2—NR1R2, —NR1—SO2—R1, —NR1—C(?O)—R1, —NR1—C(?O)—NR1R2, —SO2—NR1R2, —SO3H, —O—SO2—OR3, —O—P(?O)—(OR3)(OR4), —O—CH2—COOR3, (C1-C3)alkyl; each R? is independently hydrogen, (C1-C3)alkyl, hydroxyl, halogen, —NO2, —NR1R2, morpholinyl, morpholino, N-methylpiperazinyl, (C1-C3)fluoroalkyl, (C1-C4)alkoxy, —O—P(?O)—(OR3)(OR4), —CN, a —NH—SO2—N(CH3)2 group, or other groups and further relates to A compound of formula (IV): or a pharmaceutically acceptable salt thereof, for use for treating and/or preventing an inflammatory disease, disorder or condition, wherein V, Z, R, R?, n, and n? are as described above.

Abstract: A chimeric antigen receptor including: a binding domain, the full DAP 10 protein, the full DAP 12 protein, or a functional variant thereof, and a hook binding domain. Also, a vector system comprising one or more vector including: a nucleic acid comprising a nucleic acid sequence encoding a chimeric antigen receptor and optionally a nucleic acid encoding a hook fusion protein, preferably having a streptavidin core; wherein the nucleic acids are located on the same or on different vectors. Further, a lentiviral vector particles system, host cell and kit including the nucleic acids or vector system, and their use as a medicament, notably for immunotherapy.

Abstract: The present invention relates to a polynucleotide comprising a gene encoding a hook protein and a gene encoding a protein of interest, said protein of interest being either a secretory protein or a cell membrane-anchored protein, wherein: said gene encoding the hook protein is under the control of a first transcription-activating signal, said gene encoding the protein of interest is under the control of a second transcription-activating signal, said second transcription-activating signal allowing a lower rate or frequency of transcription initiation than the first transcription-activating signal, said hook protein is fused to a cellular compartment-retention peptide, and said protein of interest is fused to a hook protein-binding domain It also related to vectors comprising the polynucleotide, cells comprising the polynucleotide or the vector and compositions comprising the same.

Abstract: Modified monomers of a Shiga toxin B-subunit (STxB) protein including at least one of: an addition of a reactive unnatural amino acid residue at the C-terminal extremity, and/or a substitution with a reactive unnatural amino acid residue at an amino acid position among Asp 3, Lys 8, Glu 10, Tyr 11, Lys 23, Lys 27, Thr 49, Lys 53, His 58, Asn 59, and Arg 69, reference made to the numbering of STxB from Shigella dysenteriae. Also relates to STxB conjugates, and oligomers, in particular pentamers, of these modified STxB proteins and STxB conjugates; as well as to compositions including the same and their use in treatment, vaccination and diagnosis methods.

Abstract: A hook fusion protein, which includes a hook domain and at least one cytoplasmic carboxyl endoplasmic reticulum (ER) retention signal and/or at least one cytoplasmic amino terminal endoplasmic reticulum (ER) retention signal; wherein the hook fusion protein is a soluble protein that localizes in the cytoplasm. Also, a nucleic acid system for intracellular targeting control including a nucleic acid encoding a target fusion protein including a hook fusion protein, and a nucleic acid encoding a target fusion protein including a hook-binding domain; wherein the target fusion protein is a membrane protein; and wherein the hook fusion protein localizes in the ER when bound to the target fusion protein. Additionally, a vector system, viral particle system, host cell and kit include these nucleic acids. Further, the vector system, viral particle system, host cell or kit for use as a medicament, in particular for immunotherapy.